New Mouse Models of, and AAV9 Gene Therapeutics to Treat, Isolated Methylmalonic Acidemia, Cobalamin B (cblB) Type

被引：0
|
作者：
Choi, Eun-Young [1 ]
Choi, Karenna [1 ]
Li, Lina [1 ]
Venditti, Charles P. [1 ]
机构：
[1] NHGRI, MMB, OARS, NIH, Bethesda, MD USA
来源：
MOLECULAR THERAPY | 2023年 / 31卷 / 04期
关键词：
D O I：
暂无
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
126
引用
收藏
页码：67 / 68
页数：2
相关论文
共 28 条
  • [1] In Vitro and In Vivo Efficacy of Single-Strand and Self-Complementary AAV9 Vectors to Treat Isolated Cobalamin B Type Methylmalonic Acidemia
    Choi, Karenna
    Choi, Eun-Young
    Venditti, Charles P.
    MOLECULAR THERAPY, 2024, 32 (04) : 91 - 91
  • [2] Exploring the Natural History of Cobalamin B (cblB) type Methylmalonic Acidemia (MMA) to Guide the Development of Systemic AAV Gene Therapy
    Gebremariam, Abigael
    Mccoy, Samantha
    Pass, Alexandra R.
    Sloan, Jennifer L.
    Ferry, Susan
    Van Ryzin, Carol
    Choi, Eun-Young
    Shchelochkov, Oleg
    Manoli, Irini
    Venditti, Charles P.
    MOLECULAR THERAPY, 2022, 30 (04) : 478 - 478
  • [3] Deep Phenotyping of a Cobalamin B-Type (cblB) Methylmalonic Acidemia Patient Cohort Guides the Selection of Biomarkers and Outcomes for AAV Gene Therapy Clinical Trials
    Gebremariam, Abigael
    Hall, Camryn
    McCoy, Samantha
    Sloan, Jennifer L.
    Ferry, Susan C.
    Van Ryzin, Carol
    Galarreta-Aima, Carolina
    Shchelochkov, Oleg
    Manoli, Irini
    Venditti, Charles P.
    MOLECULAR THERAPY, 2024, 32 (04) : 297 - 298
  • [4] Liver directed gene therapy using AAV9 to treat a new murine model of propionic acidemia caused by Pccb deficiency
    Chandler, R. J.
    Hubbard, B. T.
    Venditti, V. P.
    HUMAN GENE THERAPY, 2018, 29 (12) : A124 - A124
  • [5] The First Viable Mouse Model of cblC Type Combined Methylmalonic Acidemia and Hyperhomocysteinemia: AAV Gene Therapy Rescues Neonatal Lethality
    Arnold, Madeline
    Sloan, Jennifer
    Achilly, Nathan
    Elliot, Gene
    Venditti, Charles
    MOLECULAR THERAPY, 2017, 25 (05) : 113 - 113
  • [6] Development of Adeno-Associated Virus (AAV9)-Mediated Gene Delivery to Treat a Mouse Model of Cockayne Syndrome
    Hatano, Silveli Suzuki
    Sriramvenugopal, Mughil
    Witko, Rachael
    Palwai, Poojan
    Rizzo, Skylar
    Vermeij, Wilbert P.
    Hoeijmakers, Jan H. J.
    Brooks, P. J.
    Kang, Peter B.
    Pacak, Christina A.
    MOLECULAR THERAPY, 2019, 27 (04) : 116 - 116
  • [7] Neonatal AAV Gene Therapy in a Viable Mouse Model of Combined Methylmalonic Acidemia and Homocystinuria, cblC Type, Is Comparable to Chronic Hydroxocobalamin Administration
    Koutsoukos, Stefanos A.
    Sloan, Jennifer L.
    Murphy, Kelsey
    Arnold, Madeline
    Achilly, Nathan
    Elliot, Gene
    Zerfas, Patricia
    Hoffmann, Victoria
    Venditti, Charles P.
    MOLECULAR THERAPY, 2021, 29 (04) : 252 - 253
  • [8] AAV9 Mediated Dars2 Gene Therapy Prevents Neurodegeneration in Two Mouse Models of LBSL
    Garofolo, Ines L.
    Liang, Yajie
    Janowski, Miroslaw
    Walczak, Piotr
    Fatemi, Ali
    Nemeth, Christina L.
    MOLECULAR THERAPY, 2024, 32 (04) : 702 - 702
  • [9] AAV9 gene replacement therapy in two mutant mouse models of CMT1X demyelinating neuropathy
    Kagiava, Alexia
    Karaiskos, Christos
    Lapathitis, George
    Sargiannidou, Irene
    Bosch, Assumpcio
    Kleopa, Kleopas
    JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, 2021, 26 (03) : 327 - 327
  • [10] AAV9 gene replacement therapy in two mutant mouse models of CMT1X demyelinating neuropathy
    Kagiava, A.
    Karaiskos, C.
    Lapathitis, G.
    Sargiannidou, I.
    Bosch, A.
    Kleopa, K. A.
    HUMAN GENE THERAPY, 2021, 32 (19-20) : A121 - A122
123